DEF 14A of Benitec Biopharma Inc., Oct 14, 2025

DEF 14A of Benitec Biopharma Inc.

Filed Oct 14, 2025 · FY20250001193125-25-239131

Open on EDGAR

  1. OUR MANAGEMENT

    OUR MANAGEMENT The following table sets forth certain information regarding those individuals currently serving as our directors (or nominated to serve as a director) and executive officers as of October 14, 2025:

  2. OUR MANAGEMENT

    | Name | Age | Position | | Dr. Jerel Banks | 50 | Chief Executive Officer, Chairman of the Board of Directors | | Megan Boston | 53 | Chief Financial Officer and Secretary, Director | | Sophie Mukadam | 44 | Chief Operating Officer | | J. Kevin Buchi (1)(2)(3) | 70 | Director | | Peter Francis (1)(2)(3) | 69 | Director | | Kishen Mehta (3) | 40 | Director | | Edward Smith (1)(2)(3) | 54 | Director |

  3. OUR MANAGEMENT

    | (1) Member of our Audit Committee. |

  4. OUR MANAGEMENT

    | (2) Member of our Compensation Committee. |

  5. OUR MANAGEMENT

    | (3) Member of our Nominating and Corporate Governance Committee. |

  6. OUR MANAGEMENT

    Dr. Jerel Banks has been a Director since October 2016, Chairman of our Board since October 2017 and Chief Executive Officer since June 2018. Dr. Banks was formerly the Chief Investment Officer of Nant Capital, LLC. Prior to joining Nant Capital, LLC, Dr. Banks served as vice president, portfolio manager and research analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments from 2012 to 2015. Prior to his tenure at Franklin Templeton Investments, he worked as a biotechnology senior equity research analyst at Sectoral Asset Management from 2011 to 2012. From 2008 to 2011, Dr. Banks worked as a biotechnology equity research analyst at Apothecary Capital, the healthcare investment management team for the family investment office of the Bass Family of Fort Worth, Texas. Dr. Banks began his career in investment management as a healthcare equity research associate at Capital Research Company where he was a member of the equity research team from 2006 to 2008. Dr. Banks earned an M.D. from Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and he holds an A.B. in Chemistry from Princeton University. Dr. Banks’ experience in the healthcare industry and finance provides valuable experience and guidance to the Board. Megan Boston has previously been Chief Executive Officer and Managing Director of several companies, including entities listed on the Australian Stock Exchange. With over 15 years of experience, Ms. Boston has been a director across a range of industries where she chaired company boards as well as board sub-committees particularly in the area of finance and risk management. Specifically, Ms. Boston has been a Director of Benitec since August 2016, Executive Director from June 2018 to December 31, 2024 and our Chief Financial Officer since January 1, 2025. Ms. Boston is also our Secretary. From 2014 until joining Benitec, Ms. Boston was CEO of listed companies on the Australian Stock Exchange and held senior executive roles at various banking institutions in the area of risk and compliance, as well as working for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce and is an Australian Chartered Accountant. Ms. Boston has also completed the company directors course diploma administered by the Australian Institute of Company Directors. We believe Ms. Boston’s operational and financial infrastructure experience gives her the necessary skills and qualifications to serve as a member of the Board. Sophie Mukadam has served as the Company’s Chief Operating Officer since December 2024 and, prior to that, served as our Associate Director, Program Management, since May 2021, and previously served as Senior Program Manager starting in May of 2019. Before joining the Company, she served as a Regulatory Affairs Associate at Regulatory Professionals, Inc. and as a regulatory consultant. Sophie Mukadam has a BA in Molecular and Cell Biology from the University of California, Berkeley, and a Certificate in Project Management for Biotechnology from the University of Washington and University of California, San Diego. J. Kevin Buchi has been a Director since April 2013. Mr. Buchi previously served as Chief Executive Officer of BioSpecifics Technologies Corp. and of TetraLogic Pharmaceuticals Corporation. Mr. Buchi served as Chief Executive Officer of Cephalon, Inc., or Cephalon, from December 2010 through its acquisition by Teva Pharmaceutical Industries Ltd in October 2011. After the acquisition Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceuticals Industries Ltd. Mr. Buchi joined Cephalon in 1991 and held various positions, including Chief Operating Officer, from January 2010 to December 2010, Chief Financial Officer and Head of Business Development prior to being appointed Chief Executive Officer. Mr. Buchi is also on the board of directors of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX). Mr. Buchi has a B.A. in chemistry from Cornell University and a Masters in Management from Kellogg Graduate School of Management at Northwestern University. He is also a Certified Public Accountant. Based on his broad executive experience in the biotechnology industry, we believe Mr. Buchi has the appropriate skills and qualifications to serve on the Board. Peter Francis has been a director since February 2006 and was previously Chairman of the Board until October 2017. Since 1993, Mr. Francis has been a partner at Francis Abourizk Lightowlers, a firm of commercial and technology lawyers with offices in Melbourne, Australia. He is a legal specialist in the areas of intellectual property and licensing and provides legal advice to corporations and research bodies. Mr. Francis completed his studies in law and jurisprudence at Monash University. Based on his substantive intellectual property background and experience with our company, we believe Mr. Francis has the appropriate skills and qualifications to serve on the Board. Kishen Mehta has been a director since June 2024. Mr. Mehta is the Chief Investment Officer and Portfolio Manager of the Averill and Averill Madison strategies at Suvretta Capital Management, LLC (“Suvretta Capital”). Mr. Mehta has over 15 years of experience in the healthcare industry. Since September 2022, Mr. Mehta has served as a director of Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on therapeutics in immunology, neuroscience, and oncology, and prior to that served as a director of its predecessor company, Biohaven Pharmaceutical Holding Company Ltd., from June 2021 until September 2022. Since 2021, Mr. Mehta has also served as President and a director of four Nasdaq-listed special-purpose acquisition companies affiliated with Suvretta Capital, Social Capital Suvretta Holdings Corp. I (from which Mr. Mehta resigned in August 2022 in connection with its business combination), Social Capital Suvretta Holdings Corp. II (which ceased operations in May 2023), Social Capital Suvretta Holdings Corp. III (from which Mr. Mehta resigned in July 2022 in connection with its business combination), and Social Capital Suvretta Holdings Corp. IV (which ceased operations in May 2023). Prior to becoming the Portfolio Manager of the investment strategy at Suvretta Capital, he served as a strategic advisor to Biohaven Pharmaceuticals, Inc. where he advised the firm on various business development, corporate strategy, and capital structure decisions. Based on his substantial experience as an investor in the healthcare industry, we believe Mr. Mehta has the appropriate skills and qualifications to serve on the board. Edward Smith has been a director since April 2020 and brings more than 20 years of experience in executive finance and operations leadership in the biotechnology industry to our Board. Mr. Smith presently serves as Chief Financial Officer of Reunion Neuroscience, Inc., a biopharmaceutical company focused on treating depression and other mental health disorders. Prior to joining Reunion, Mr. Smith served as CFO and took public LAVA Therapeutics N.V. (Nasdaq: LVTX), Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) and PolyMedix, Inc. (Nasdaq: PYMX). Prior to that, he was executive director of finance at InKine Pharmaceutical Company, Inc., now part of Valeant Pharmaceuticals International Inc. Earlier in his career, he held various positions of increasing responsibility in public accounting, most recently in the audit practice at Deloitte. Based on his extensive finance and operations background in the biotechnology industry, we believe Mr. Smith has the appropriate skill and qualifications to serve on the Board.

  7. OUR MANAGEMENT

    There are no family relationships among any of our directors or executive officers and no arrangements or understandings with major stockholders, customers, suppliers or others pursuant to which any of our directors or members of senior management was selected as such, except Dr. Banks was appointed by Nant Capital as a Director in October 2016 following the acquisition by Nant Capital, LLC of a significant percentage of Benitec’s then- outstanding ordinary shares, and Mr. Mehta was appointed by Suvretta Capital as a Director pursuant to the previously disclosed Board Designation Agreement entered into in April 2024 in connection with the April 2024 private placement. The business addresses for each of our directors and executive officers is 3940 Trust Way, Hayward, California 94545.

  8. Board of Directors

    Board of Directors Our Board held a total of eleven meetings during the last fiscal year. Our Board has three standing committees — an Audit Committee established in accordance with section 3(a)(58)(A) of the Securities Exchange Act of 1934 (our “Audit Committee”), a Compensation Committee (our “Compensation Committee”) and a Nominating and Corporate Governance Committee (our “Nominating Committee”). Our Audit Committee, Compensation Committee and Nominating Committee each have a charter, which is available at the “Corporate Governance” section under the “For Investors” tab on our website at www.benitec.com.

  9. EXECUTIVE COMPENSATION

    EXECUTIVE COMPENSATION As a “smaller reporting company” we have opted to comply with the scaled executive compensation disclosure rules applicable to “smaller reporting companies” (as such term is defined under applicable securities laws). Our named executive officers, or our “NEOs”, for the fiscal year ended June 30, 2025 were Dr. Jerel A. Banks, our Executive Chairman and Chief Executive Officer, Megan Boston, our Chief Financial Officer and Secretary, and Sophie Mukadam, our Chief Operating Officer. The Company’s named executive officer compensation program is designed to incentivize our named executive officers to grow our business and further link the interests of our named executive officers with our stockholders. We provide our named executive officers with an annual base salary as a fixed, stable form of compensation, certain cash incentive opportunities as noted below to reward achievement of short-term goals, and, in prior fiscal years, we have granted our named executive officers stock options with multi-year vesting schedules to further align their compensation with our stockholders’ long-term interests. We have also entered into employment agreements with Dr. Banks and Ms. Boston that provide for a fixed notice period in connection with certain terminations of employment. The employment agreements and our named executive officer compensation program generally are described in greater detail below under the heading “Narrative Disclosure to Summary Compensation Table”.

  10. Summary Compensation Table

    Summary Compensation Table The following table sets forth information regarding compensation earned by our NEOs during the fiscal year ended June 30, 2025 and the fiscal year ended June 30, 2024:

  11. Summary Compensation Table

    | Named Executive Officer and Principal Position | Fiscal Year | Salary ($)(1) | Bonus ($)(2) | Option Awards ($)(3) | All Other Compensation ($) | Total ($) | | Dr. Jerel Banks, M.D. Ph.D | 2025 | 661,100 | 366,850 | 24,795,540 | 41,546(5) | 25,865,036 | | Chairman and Chief Executive Officer | 2024 | 627,900 | 360,360 | 2,133,085 | 37,992 | 3,159,337 | | Megan Boston | 2025 | 445,610 | 175,000 | 7,728,480 | 250,203(6) | 8,599,293 | | Chief Financial Officer, Secretary | 2024 | 344,541 | 161,580(4) | 914,418 | 18,038 | 1,438,577 | | Sophie Mukadam (7) | 2025 | 340,846 | 200,000 | 3,175,800 | 58,747(8) | 3,775,393 | | Chief Operating Officer | | | | | | |

  12. Summary Compensation Table

    | (1) From July 1, 2024 through December 31, 2024, Dr. Banks’, Ms. Boston’s, and Ms. Mukadam’s annual base salaries were $655,200, $A548,100 ($350,784 converted using a conversion rate of A$1.00 to $0.64), and $181,692 , respectively. Effective January 1, 2025, Dr. Banks’, Ms. Boston’s, and Ms. Mukadam’s annual base salaries were increased to $667,000, $415,000, and $500,000, respectively. Effective March 1, 2025, Ms. Boston’s annual base salary was increased to $531,900. |

  13. Summary Compensation Table

    | (2) Reflects discretionary bonuses paid to Dr. Banks, Ms. Boston, in connection with their performance during the fiscal years ending June 30, 2025 and June 30, 2024, respectively and to Ms. Mukadam in connection with her performance during fiscal year ending June 30, 2025. |

  14. Summary Compensation Table

    | (3) Amount represents the aggregate grant date fair value of stock and option awards granted by the Company in the fiscal year ended June 30, 2024, computed in accordance with FASB ASC Topic 718. For further information on how we account for stock-based compensation, see Note 10 to the Company’s consolidated financial statements for the year ended June 30, 2024, included in this Annual Report. These amounts reflect the Company’s accounting expense for these awards and do not correspond to the actual amounts, if any, that will be recognized by the NEOs. |

  15. Summary Compensation Table

    | (4) Ms. Boston’s discretionary annual bonus was paid in Australian dollars and has been converted to U.S. dollars using a conversion rate of A$1.00 to $0.67 for the fiscal year ended June 30, 2024. |

  16. Summary Compensation Table

    | (5) Amount reflects company-paid health and life insurance premiums. |

  17. Summary Compensation Table

    | (6) Amount reflects the Company’s compulsory contributions to Ms. Boston’s superannuation account and pay out of leave entitlements. The superannuation contributions were paid in Australian dollars and were converted to U.S. dollars using a conversion rate of A$1.00 to $0.6475, and A$1.00 to $0. 6559, for the fiscal years ended June 30, 2025 and June 30, 2024. Ms. Boston resigned from Benitec Biopharma Pty Ltd and was therefore paid out annual leave and long service leave prior to relocating to the USA |

  18. Summary Compensation Table

    | (7) Ms. Mukadam was appointed the Company’s Chief Operating Officer on January 1, 2025. |

  19. Summary Compensation Table

    | (8) Amount reflects company-paid health and life insurance premiums and 401(k) employer matching contributions. |

  20. Outstanding Equity Awards at Fiscal Year-End

    Outstanding Equity Awards at Fiscal Year-End The following table sets forth information regarding outstanding equity or equity-linked awards for each of our NEOs as of June 30, 2025.

  21. Outstanding Equity Awards at Fiscal Year-End

    | | | Option Awards | | | | | Named Executive Officer | Grant Date | Number of Securities Underlying Unexercised Options (#)— Exercisable | Number of Securities Underlying Unexercised Options (#)— Unexercisable | Option Exercise Price ($) | Option Expiration Date | | Dr. Jerel A. Banks, M.D. Ph.D. | 12/9/2024(1)(3) | 288,750 | 2,021,250 | 12.18 | 12/8/2034 | | Chairman and Chief Executive Officer | 3/6/2024(1)(2) | 155,518 | 311,036 | 5.21 | 3/5/2034 | | | 6/13/2023(1)(2) | 13,997 | 6,997 | 3.91 | 6/12/2033 | | Megan Boston | 12/9/2024(1)(3) | 90,000 | 630,000 | 12.18 | 12/8/2034 | | Chief Financial Officer, Secretary | 3/6/2024(1)(2) | 66,668 | 133,336 | 5.21 | 3/5/2034 | | | 6/13/2023(1)(2) | 6,001 | 2,999 | 3.91 | 6/12/2033 | | Sophie Mukadam | 12/27/2024(1)(3) | 37,500 | 262,500 | 12.00 | 12/26/2034 | | Chief Operating Officer | 3/6/2024(1)(2) | 33,333 | 66,667 | 5.21 | 3/5/2034 | | | 6/13/2023(1)(2) | 3,529 | 1,765 | 3.91 | 6/12/2033 |

  22. Outstanding Equity Awards at Fiscal Year-End

    | (1) The option awards were granted under the 2020 Plan. |

  23. Outstanding Equity Awards at Fiscal Year-End

    | (2) The shares subject to each of the option awards vest in substantially equal installments on each of the first, second and third anniversaries of the grant date, generally subject to continued employment through the applicable vesting date. |

  24. Outstanding Equity Awards at Fiscal Year-End

    | (3) The shares subject to each of the option awards vest in sixteen substantially equal quarterly installments on the last day of each full fiscal quarter of the Company ending after the Grant Date, with the first vesting date occurring on March 31, 2025, generally subject to continued employment through the applicable vesting date. |

  25. Termination or Change in Control Benefits

    Termination or Change in Control Benefits The employment agreements with Dr. Banks and Ms. Boston provide for specified notice periods (or pay in lieu of notice) if the Company terminates the employment of our NEOs under certain circumstances, as described above in the “Employment Agreements with our NEOs” section. Upon the consummation of a Change in Control (as defined in the 2020 Plan), all unvested stock options granted pursuant to the 2020 Plan will immediately vest as of immediately prior to the Change in Control. Our NEOs are not eligible to receive any additional payments or benefits in connection with their termination of employment or in connection with the Company’s change in control.

  26. Pay Versus Performance Disclosure

    Pay Versus Performance Disclosure As required by Item 402(v) of Regulation S-K, which was mandated by Section 953(a) of the Dodd-Frank Act, we are providing the following information about the relationship between “compensation actually paid” to our principal executive officer (“PEO”) and average “compensation actually paid” (“CAP”) to each of our NEOs and the financial performance of the Company for the Company’s fiscal years ended June 30, 2025 (“Fiscal 2025”), June 30, 2024 (“Fiscal 2024”), and June 30, 2023 (“Fiscal 2023”), in each case calculated in a manner consistent with SEC rules.

  27. Pay Versus Performance Disclosure

    | Year | Summary Compensation Table Total for PEO(1) | Compensation Actually Paid to PEO(1)(2) | Average Summary Compensation Table Total for Non-PEO NEOs (2)(3) | Average Compensation Actually Paid to Non-PEO NEOs (2)(3) | Investment Based Total Shareholder Return (4) | Income (loss) (in thousands) | | 2025 | $25,865,036 | $26,724,611 | $6,187,343 | $6,794,411 | $67.38 | $(37,864) | | 2024 | $3,159,337 | $4,288,885 | $1,438,577 | $1,942,302 | $72.40 | $(21,814) | | 2023 | $918,725 | $701,866 | $469,457 | $360,893 | $(79.44) | $(14,901) |

  28. Pay Versus Performance Disclosure

    | (1) The PEO reflected in these columns for Fiscal 2025, Fiscal 2024, and Fiscal 2023 is Dr. Jerel A. Banks, M.D. Ph.D. |

  29. Pay Versus Performance Disclosure

    | (2) CAP to our PEO and Non-PEO NEOs is calculated based on the “Total Compensation” reported in the Summary Compensation Table (“SCT”) for each of the applicable fiscal years, adjusted to exclude and include certain items in accordance with Item 402(v) of Regulation S-K as follows. |

  30. Pay Versus Performance Disclosure

    PEO SCT Total to CAP Reconciliation:

  31. Pay Versus Performance Disclosure

    | | | | Additions to SCT Total(ii) | | | | | Fiscal Year | SCT Total | Deductions from SCT Total (i) | Fair Value of Current Year Equity Awards for Fiscal Year 2025 | Change in Value of Prior Years’ Awards Unvested for Fiscal Year 2025 | Change in Value of Prior Years’ Awards that Vested in Fiscal Year 2025 | CAP | | 2025 | $25,865,036 | $24,795,540 | $23,650,026 | $1,263,672 | $741,417 | $26,724,611 | | 2024 | $3,159,337 | $2,133,085 | $2,933,318 | $55,808 | $273,507 | $4,288,885 | | 2023 | $918,725 | $70,657 | $74,271 | $(230,188) | $9,715 | $701,866 |

  32. DIRECTOR COMPENSATION

    DIRECTOR COMPENSATION The following table shows the total compensation paid to the Company’s directors (other than any such directors who are also NEOs) for the fiscal year ended June 30, 2025.

  33. DIRECTOR COMPENSATION

    | Name | Fees Earned or Paid in Cash ($)(2) | Option Awards ($)(3) | All Other Compensation ($)(4) | Total ($) | | J. Kevin Buchi | 64,000 | 368,410 | — | 432,410 | | Peter Francis | 52,542 | 368,410 | 6,041 | 426,993 | | Kishen Mehta | — | 368,410 | — | 368,410 | | Edward F. Smith | 56,500 | 368,410 | — | 424,910 |

  34. DIRECTOR COMPENSATION

    | (1) For information regarding the compensation of Dr. Banks and Ms. Boston, see “Summary Compensation Table.” |

  35. DIRECTOR COMPENSATION

    | (2) Fees paid to Mr. Francis were paid in Australian dollars and have been converted to U.S. dollars using a conversion rate of A$1.00 to $0.6475 for the fiscal year ended June 30, 2025. |

  36. DIRECTOR COMPENSATION

    | (3) Amount represents the aggregate grant date fair value of stock and option awards granted by the Company in the fiscal year ended June 30, 2025, computed in accordance with FASB ASC Topic 718. For further information on how we account for stock-based compensation, see Note 10 to the Company’s consolidated financial statements for the year ended June 30, 2025 included in this Annual Report. These amounts reflect the Company’s accounting expense for these awards and do not correspond to the actual amounts, if any, that will be recognized by the directors. |

  37. DIRECTOR COMPENSATION

    | (4) For information regarding other compensation of all directors, see “Narrative Disclosure to Director Compensation Table.” |

  38. DIRECTOR COMPENSATION

    For each director, the aggregate number of option awards outstanding at fiscal year-end for the fiscal year ended June 30, 2025 is set forth below.:

  39. DIRECTOR COMPENSATION

    | Name | Option Awards (#) | | J. Kevin Buchi | 73,503 | | Peter Francis | 73,503 | | Kishen Mehta | 35,000 | | Edward F. Smith | 73,503 |

  40. Narrative Disclosure to Director Compensation Table

    Narrative Disclosure to Director Compensation Table Dr. Banks and Ms. Boston, who are executive officers and employees of the Company, do not receive annual fees with respect to their service on the Board. The annual fees for the fiscal year ended June 30, 2025 paid to our non-employee directors were:

  41. Narrative Disclosure to Director Compensation Table

    | • | an annual cash retainer of $40,000; |

  42. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $15,000 to the chair of the Audit Committee; |

  43. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $10,000 to the chair of the Compensation Committee; |

  44. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $7,500 to the chair of the Nominating Committee; |

  45. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $7,500 to a non-chair member of the Audit Committee; |

  46. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $5,000 to a non-chair member of the Compensation Committee; and |

  47. Narrative Disclosure to Director Compensation Table

    | • | an additional annual cash retainer of $4,000 to a non-chair member of the Nominating Committee. |

  48. Narrative Disclosure to Director Compensation Table

    In addition to the cash fees paid to our non-employee directors, the Board granted each of Messrs. Buchi, Francis, Smith and Mehta awards for 35,000 options on December 9, 2024. The option awards vest in full on the earlier of immediately prior to the next annual meeting of stockholders and the first anniversary of the grant date. In addition, the Company makes a superannuation contribution on Mr. Francis’ behalf in the amount of $6,041.

  49. ELECTION OF DIRECTORS

    ELECTION OF DIRECTORS Our Board currently consists of six directors divided into three classes — Class I (Mr. Smith and Mr. Mehta), Class II (Mr. Buchi and Mr. Francis) and Class III (Dr. Banks and Ms. Boston) — with the directors in each class holding office for staggered terms of three years each or until their successors have been duly elected and qualified. Dr. Banks’ and Ms. Boston’s terms expire at the Annual Meeting. Accordingly, two Class III directors will be elected at the Annual Meeting. The nominees for election as Class III directors are Dr. Banks and Ms. Boston. The Class III directors will serve until our 2028 Annual Meeting of Stockholders and until his successor is elected and qualified. Assuming the nominees are elected, we will have six directors serving as follows:

  50. ELECTION OF DIRECTORS

    | Class I director: Edward Smith and Kishen Mehta | Terms expires at our 2026 annual meeting of stockholders. | | Class II directors: J. Kevin Buchi and Peter Francis | Terms expire at our 2027 Annual Meeting of stockholders. | | Class III directors: Dr. Jerel Banks and Megan Boston | Terms expire at our 2025 annual meeting of stockholders, and at our 2028 annual meeting assuming re-election. |

  51. ELECTION OF DIRECTORS

    The accompanying proxy card grants the proxy holder the power to vote the proxy for a substitute nominee in the event that one of the nominees become unavailable to serve as a Class III director. Management presently has no knowledge that the nominees will refuse or be unable to serve as Class III directors for their prescribed terms.

  52. Director Nominees: Dr. Jerel Banks and Megan Boston

    Director Nominees: Dr. Jerel Banks and Megan Boston See above under “Our Management” for the biographical information of Dr. Banks and Ms. Boston.